中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2841-2845

Advances in the mechanism of action of silent information regulator 1 in alcoholic liver disease and related pharmaceutical studies

DOI: 10.3969/j.issn.1001-5256.2022.12.030
  • 1.

    The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450018, China

  • 2.

    Spleen, Stomach and Hepatobiliary Department, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

National Natural Science Foundation of China (Joint Fund) (U1504825);

Key Scientific Research Projects of Colleges and Universities in Henan Province (20A360014);

Henan Provincial Top talents training Program of Traditional Chinese Medicine (Yuwei Traditional Chinese Medicine 2021 No.15)

More Information
  • Corresponding author: LIU Jiangkai, xmlc001@126.com (ORCID: 0000-0002-1529-5089)
  • Received Date: 2022-05-07
  • Accepted Date: 2022-06-17
  • Published Date: 2022-12-20
    Abstract
  • Alcoholic liver disease (ALD) is one of the main chronic liver diseases in the world, and the prevalence rate of ALD is increasing year by year in China, with a trend of earlier age of onset. Silent information regulator 1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent deacetylase and plays a significant role in cell metabolism, oxidative stress, and inflammation, and it is expected to become a new therapeutic target for ALD. This article reviews the mechanism of action of SIRT1 in ALD and related pharmaceutical studies, in order to provide a reference and strategies for further research on the pathogenesis of ALD and its potential therapeutic targets.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev DisPrimers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7.
    [2]
    World Health Organization. Global status report on alcohol and health 2018[M]. World Health Organization, 2019.
    [3]
    WANG WJ, XIAO P, XU HQ, et al. Growing burden of alcoholic liver disease in China: A review[J]. World J Gastroenterol, 2019, 25(12): 1445-1456. DOI: 10.3748/wjg.v25.i12.1445.
    [4]
    LIU Y, SU L. Guidline for primary care of alcoholic liver disease(2019)[J]. J Clin Hepatol, 2021, 37(1): 36-40. DOI: 10.3969/j.issn.1001-5256.2021.01.008.

    刘岩, 苏琳. 酒精性肝病基层诊疗指南(2019年)[J]. 临床肝胆病杂志, 2021, 37(1): 36-40. DOI: 10.3969/j.issn.1001-5256.2021.01.008.
    [5]
    HYUN J, HAN J, LEE C, et al. Pathophysiological aspects of alcohol metabolism in the liver[J]. Int J Mol Sci, 2021, 22(11): 5717. DOI: 10.3390/ijms22115717.
    [6]
    SONG Q, CHEN Y, WANG J, et al. ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development[J]. J Hepatol, 2020, 73(4): 783-793. DOI: 10.1016/j.jhep.2020.04.038.
    [7]
    KANG H, PARK YK, LEE JY. Nicotinamide riboside, an NAD+ precursor, attenuates inflammation and oxidative stress by activating sirtuin 1 in alcohol-stimulated macrophages[J]. Lab Invest, 2021, 101(9): 1225-1237. DOI: 10.1038/s41374-021-00599-1.
    [8]
    YIN H, HU M, LIANG X, et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver[J]. Gastroenterology, 2014, 146(3): 801-811. DOI: 10.1053/j.gastro.2013.11.008.
    [9]
    CHEN C, ZHOU M, GE Y, et al. SIRT1 and aging related signaling pathways[J]. Mech Ageing Dev, 2020, 187: 111215. DOI: 10.1016/j.mad.2020.111215.
    [10]
    ZHOU Z, YE TJ, DECARO E, et al. Intestinal SIRT1 deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis[J]. Am J Pathol, 2020, 190(1): 82-92. DOI: 10.1016/j.ajpath.2019.09.012.
    [11]
    NAKAMURA K, ZHANG M, KAGEYAMA S, et al. Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury[J]. J Hepatol, 2017, 67(6): 1232-1242. DOI: 10.1016/j.jhep.2017.08.010.
    [12]
    HERSKOVITS AZ, GUARENTE L. Sirtuin deacetylases in neurodegenerative diseases of aging[J]. Cell Res, 2013, 23(6): 746-758. DOI: 10.1038/cr.2013.70.
    [13]
    TANNO M, SAKAMOTO J, MIURA T, et al. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1[J]. J Biol Chem, 2007, 282(9): 6823-6832. DOI: 10.1074/jbc.M609554200.
    [14]
    YANG X, DONG WB, LEI XP, et al. Resveratrol suppresses hyperoxia-induced nucleocytoplasmic shuttling of SIRT1 and ROS production in PBMC from preterm infants in vitro[J]. J Matern Fetal Neonatal Med, 2018, 31(9): 1142-1150. DOI: 10.1080/14767058.2017.1311310.
    [15]
    GOODMAN RP, MARKHARD AL, SHAH H, et al. Hepatic NADH reductive stress underlies common variation in metabolic traits[J]. Nature, 2020, 583(7814): 122-126. DOI: 10.1038/s41586-020-2337-2.
    [16]
    CUI X, CHEN Q, DONG Z, et al. Inactivation of Sirt1 in mouse livers protects against endotoxemic liver injury by acetylating and activating NF-κB[J]. Cell Death Dis, 2016, 7(10): e2403. DOI: 10.1038/cddis.2016.270.
    [17]
    DUAN FF, CHENG J, YANG S. Research progress on liver transplantation for alcoholic liver disease[J]. Organ Transplantation, 2020, 11(3): 413-418. DOI: 10.3969/j.issn.1674-7445.2020.03.016.

    段方方, 成军, 杨松. 酒精性肝病肝移植的研究进展[J]. 器官移植, 2020, 11(3): 413-418. DOI: 10.3969/j.issn.1674-7445.2020.03.016.
    [18]
    NOWAK AJ, RELJA B. The impact of acute or chronic alcohol intake on the NF-κB signaling pathway in alcohol-related liver disease[J]. Int J Mol Sci, 2020, 21(24): 9407. DOI: 10.3390/ijms21249407.
    [19]
    XIONG X, YU J, FAN R, et al. NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice[J]. PLoS One, 2019, 14(2): e0212523. DOI: 10.1371/journal.pone.0212523.
    [20]
    KANG H, KIM MB, PARK YK, et al. A mouse model of the regression of alcoholic hepatitis: Monitoring the regression of hepatic steatosis, inflammation, oxidative stress, and NAD+ metabolism upon alcohol withdrawal[J]. J Nutr Biochem, 2022, 99: 108852. DOI: 10.1016/j.jnutbio.2021.108852.
    [21]
    LIU CY, WANG M, YU HM, et al. Ferroptosis is involved in alcohol-induced cell death in vivo and in vitro[J]. Biosci Biotechnol Biochem, 2020, 84(8): 1621-1628. DOI: 10.1080/09168451.2020.1763155.
    [22]
    YOU M, ARTEEL GE. Effect of ethanol on lipid metabolism[J]. J Hepatol, 2019, 70(2): 237-248. DOI: 10.1016/j.jhep.2018.10.037.
    [23]
    PI A, JIANG K, DING Q, et al. Alcohol abstinence rescues hepatic steatosis and liver injury via improving metabolic reprogramming in chronic alcohol-fed mice[J]. Front Pharmacol, 2021, 12: 752148. DOI: 10.3389/fphar.2021.752148.
    [24]
    HOU Y, SU B, CHEN P, et al. Association of SIRT1 gene polymorphism and its expression for the risk of alcoholic fatty liver disease in the Han population[J]. Hepatol Int, 2018, 12(1): 56-66. DOI: 10.1007/s12072-017-9836-8.
    [25]
    SILVA J, SPATZ MH, FOLK C, et al. Dihydromyricetin improves mitochondrial outcomes in the liver of alcohol-fed mice via the AMPK/Sirt-1/PGC-1α signaling axis[J]. Alcohol, 2021, 91: 1-9. DOI: 10.1016/j.alcohol.2020.10.002.
    [26]
    NAGAPPAN A, KIM JH, JUNG DY, et al. Cryptotanshinone from the salvia miltiorrhiza bunge attenuates ethanol-induced liver injury by activation of AMPK/SIRT1 and Nrf2 signaling pathways[J]. Int J Mol Sci, 2019, 21(1): 265. DOI: 10.3390/ijms21010265.
    [27]
    LEE HI, YUN KW, SEO KI, et al. Scopoletin prevents alcohol-induced hepatic lipid accumulation by modulating the AMPK-SREBP pathway in diet-induced obese mice[J]. Metabolism, 2014, 63(4): 593-601. DOI: 10.1016/j.metabol.2014.01.003.
    [28]
    PONUGOTI B, KIM DH, XIAO Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism[J]. J Biol Chem, 2010, 285(44): 33959-33970. DOI: 10.1074/jbc.M110.122978.
    [29]
    BI L, JIANG Z, ZHOU J. The role of lipin-1 in the pathogenesis of alcoholic fatty liver[J]. Alcohol Alcohol, 2015, 50(2): 146-151. DOI: 10.1093/alcalc/agu102.
    [30]
    LI Y, ZHOU J. Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease[J]. Exp Biol Med (Maywood), 2017, 242(11): 1117-1125. DOI: 10.1177/1535370217707729.
    [31]
    YIN H, HU M, ZHANG R, et al. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1[J]. J Biol Chem, 2012, 287(13): 9817-9826. DOI: 10.1074/jbc.M111.333534.
    [32]
    YAO YL, HAN X, LI ZM, et al. Acanthoic acid can partially prevent alcohol exposure-induced liver lipid deposition and inflammation[J]. Front Pharmacol, 2017, 8: 134. DOI: 10.3389/fphar.2017.00134.
    [33]
    CHEN X, XU Y, DENNING KL, et al. PPARα agonist WY-14, 643 enhances ethanol metabolism in mice: Role of catalase[J]. Free Radic Biol Med, 2021, 169: 283-293. DOI: 10.1016/j.freeradbiomed.2021.04.018.
    [34]
    YUE R, CHEN GY, XIE G, et al. Activation of PPARα-catalase pathway reverses alcoholic liver injury via upregulating NAD synthesis and accelerating alcohol clearance[J]. Free Radic Biol Med, 2021, 174: 249-263. DOI: 10.1016/j.freeradbiomed.2021.08.005.
    [35]
    ATTAL N, MARRERO E, THOMPSON KJ, et al. Cytochrome P4502E1-dependent hepaticethanol metabolism induces fatty acid-binding protein 4 and steatosis[J]. Alcohol Clin Exp Res, 2022, 46(6): 928-940. DOI: 10.1111/acer.14828.
    [36]
    CHEN H, SHEN F, SHERBAN A, et al. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease[J]. Hepatology, 2018, 68(2): 496-514. DOI: 10.1002/hep.29849.
    [37]
    LEE SE, KOH H, JOO DJ, et al. Induction of SIRT1 by melatonin improves alcohol-mediated oxidative liver injury by disrupting the CRBN-YY1-CYP2E1 signaling pathway[J]. J Pineal Res, 2020, 68(3): e12638. DOI: 10.1111/jpi.12638.
    [38]
    ZHOU Y, WANG S, WAN T, et al. Cyanidin-3-O-β-glucoside inactivates NLRP3 inflammasome and alleviates alcoholic steatohepatitis via SirT1/NF-κB signaling pathway[J]. Free Radic Biol Med, 2020, 160: 334-341. DOI: 10.1016/j.freeradbiomed.2020.08.006.
    [39]
    RAMIREZ T, LI YM, YIN S, et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression[J]. J Hepatol, 2017, 66(3): 601-609. DOI: 10.1016/j.jhep.2016.11.004.
    [40]
    WU Y, LIU X, ZHOU Q, et al. Silent information regulator 1 (SIRT1) ameliorates liver fibrosis via promoting activated stellate cell apoptosis and reversion[J]. Toxicol Appl Pharmacol, 2015, 289(2): 163-176. DOI: 10.1016/j.taap.2015.09.028.
    [41]
    KIM MJ, AN HJ, KIM DH, et al. Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice[J]. Bioorg Med Chem Lett, 2018, 28(4): 684-688. DOI: 10.1016/j.bmcl.2018.01.021.
    [42]
    LIU X, ZHAO H, LUO C, et al. Acetaminophen responsive miR-19b modulates SIRT1/Nrf2 signaling pathway in drug-induced hepatotoxicity[J]. Toxicol Sci, 2019, 170(2): 476-488. DOI: 10.1093/toxsci/kfz095.
    [43]
    RAWAT D, CHHONKER SK, NAIK RA, et al. Modulation of antioxidant enzymes, SIRT1 and NF-κB by resveratrol and nicotinamide in alcohol-aflatoxin B1-induced hepatocellular carcinoma[J]. J Biochem Mol Toxicol, 2021, 35(1): e22625. DOI: 10.1002/jbt.22625.
    [44]
    ZHOU YN, XU PJ, DENG CF, et al. Chrysin alleviated ethanol-induced alcoholic liver injury via SIRT1/AMPK signaling pathway[J]. Chin Pharmacol Bull, 2022, 38(1): 159-160. DOI: 10.3969/j.issn.1001-1978.2022.01.028.

    周禹柠, 徐培杰, 邓楚凡, 等. 白杨素通过SIRT1/AMPK信号通路缓解乙醇诱导的酒精性肝损伤[J]. 中国药理学通报, 2022, 38(1): 159-160. DOI: 10.3969/j.issn.1001-1978.2022.01.028.
    [45]
    YANG T, SONG HP, CHEN Z, et al. Effect and mechanism of Yinchenhao decoction on acute alcoholic liver injury based on SIRT1/AMPK signaling pathway[J]. Pharmocol Clin Chin Mater Med, 2022, 38(1): 36-40. DOI: 10.13412/j.cnki.zyyl.zyyl.2022.01.019.

    杨焘, 宋厚盼, 陈哲, 等. 基于SIRT1/AMPK信号通路探讨茵陈蒿汤治疗急性酒精性肝损伤的效应及机制[J]. 中药药理与临床, 2022, 38(1): 36-40. DOI: 10.13412/j.cnki.zyyl.2022.01.019.
    [46]
    WEI Z, JIA J, HENG G, et al. Sirtuin-1/Mitochondrial ribosomal protein S5 axis enhances the metabolic flexibility of liver cancer stem cells[J]. Hepatology, 2019, 70(4): 1197-1213. DOI: 10.1002/hep.30622.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1742) PDF downloads(77) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return